272 related articles for article (PubMed ID: 37874473)
21. Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma.
Licht P; Mailänder V
Cells; 2022 Jan; 11(3):. PubMed ID: 35159138
[TBL] [Abstract][Full Text] [Related]
22. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
Bobrowicz M; Fassnacht C; Ignatova D; Chang YT; Dimitriou F; Guenova E
Int Arch Allergy Immunol; 2020; 181(10):733-745. PubMed ID: 32690848
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous T cell lymphoma: update on treatment.
Wollina U
Int J Dermatol; 2012 Sep; 51(9):1019-36. PubMed ID: 22909354
[TBL] [Abstract][Full Text] [Related]
26. Single-cell RNA sequencing unveils the communications between malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphoma.
Du Y; Cai Y; Lv Y; Zhang L; Yang H; Liu Q; Hong M; Teng Y; Tang W; Ma R; Wu J; Wu J; Wang Q; Chen H; Li K; Feng J
Cancer Lett; 2022 Dec; 551():215972. PubMed ID: 36265653
[TBL] [Abstract][Full Text] [Related]
27. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
Mishra A; La Perle K; Kwiatkowski S; Sullivan LA; Sams GH; Johns J; Curphey DP; Wen J; McConnell K; Qi J; Wong H; Russo G; Zhang J; Marcucci G; Bradner JE; Porcu P; Caligiuri MA
Cancer Discov; 2016 Sep; 6(9):986-1005. PubMed ID: 27422033
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma.
Shen X; Wang B; Li K; Wang L; Zhao X; Xue F; Shi R; Zheng J
J Invest Dermatol; 2018 Sep; 138(9):2024-2032. PubMed ID: 29559342
[TBL] [Abstract][Full Text] [Related]
29. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.
Gaydosik AM; Tabib T; Geskin LJ; Bayan CA; Conway JF; Lafyatis R; Fuschiotti P
Clin Cancer Res; 2019 Jul; 25(14):4443-4454. PubMed ID: 31010835
[TBL] [Abstract][Full Text] [Related]
30. Current status of cutaneous T-cell lymphoma: molecular diagnosis, pathogenesis, therapy and future directions.
Dippel E; Klemke CD; Goerdt S
Onkologie; 2003 Oct; 26(5):477-83. PubMed ID: 14605466
[TBL] [Abstract][Full Text] [Related]
31. The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.
Olszewska B; Gleń J; Zabłotna M; Nowicki RJ; Sokołowska-Wojdyło M
Arch Dermatol Res; 2021 Jan; 313(1):25-31. PubMed ID: 32270320
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
33. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.
Kopp KL; Ralfkiaer U; Gjerdrum LM; Helvad R; Pedersen IH; Litman T; Jønson L; Hagedorn PH; Krejsgaard T; Gniadecki R; Bonefeld CM; Skov L; Geisler C; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
Cell Cycle; 2013 Jun; 12(12):1939-47. PubMed ID: 23676217
[TBL] [Abstract][Full Text] [Related]
34. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
Lansigan F; Foss FM
Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma.
Han Z; Estephan RJ; Wu X; Su C; Yuan YC; Qin H; Kil SH; Morales C; Schmolze D; Sanchez JF; Tian L; Yu J; Kortylewski M; Rosen ST; Querfeld C
J Invest Dermatol; 2022 Mar; 142(3 Pt A):603-612.e7. PubMed ID: 34774537
[TBL] [Abstract][Full Text] [Related]
36. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
McGirt LY; Adams CM; Baerenwald DA; Zwerner JP; Zic JA; Eischen CM
J Invest Dermatol; 2014 Apr; 134(4):1101-1107. PubMed ID: 24304814
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.
Schlaak M; Pickenhain J; Theurich S; Skoetz N; von Bergwelt-Baildon M; Kurschat P
Cochrane Database Syst Rev; 2012 Jan; 1():CD008908. PubMed ID: 22258991
[TBL] [Abstract][Full Text] [Related]
38. Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma.
Kopp KL; Ralfkiaer U; Nielsen BS; Gniadecki R; Woetmann A; Ødum N; Ralfkiaer E
APMIS; 2013 Nov; 121(11):1020-4. PubMed ID: 24033365
[TBL] [Abstract][Full Text] [Related]
39. Non-coding RNAs in the epigenetic landscape of cutaneous T-cell lymphoma.
Adeeb M; Therachiyil L; Moton S; Buddenkotte J; Alam MA; Uddin S; Steinhoff M; Ahmad A
Int Rev Cell Mol Biol; 2023; 380():149-171. PubMed ID: 37657857
[TBL] [Abstract][Full Text] [Related]
40. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
